MSarsCoV2 - Development of a recombinant viral vector vaccine for active immunization of at-risk groups against clinical SARS-2 coronavirus infections.

The MSarsCoV2 vaccine project involves the preclinical and clinical development of a recombinant viral MVA vector vaccine against covid-19 and focuses in particular on particularly vulnerable target groups (very old or pre-diseased people). For active immunisation, a carrier virus that is not capable of replication in humans and has been tested for a long time is used, which produces the spike protein of the SARS 2 coronavirus in the vaccinated human and induces the formation of neutralising antibodies as well as a cellular (T-cell) immune response. The vaccine vector was developed at Ludwig-Maximilians-Universität (LMU) Munich. The LMU is substantially involved in the clinical development with other sites of the German Center for Infection Research (DZIF). Data already available speak for the immunological efficacy. Clinical development is being carried out with multi-centre clinical trials at partner institutions in Germany and abroad and is intended to create the prerequisite for approval of the vaccine. In parallel, the manufacturing technology for commercial production is being optimised and expanded at IDT Biologika GmbH. Innovative analytical technologies will support rapid production and testing. IDT Biologika GmbH will increase the capacities for the production of the active ingredient and sterile filling to ensure the provision of the required vaccine doses for the demands.